Search
Ergometrine
go.drugbank.com/drugs/DB01253ApprovedInvestigationalAn ergot alkaloid with uterine and vascular smooth muscle contractile properties.
Categories: Adrenergic alpha-1 Receptor Agonists, P-glycoprotein inhibitorsDiethylcarbamazine
go.drugbank.com/drugs/DB00711ApprovedInvestigationalVet approvedWithdrawnAn anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.
GC-376 free acid
go.drugbank.com/drugs/DB15796ExperimentalThese results suggest that GC-376, and its metabolites may have therapeutic potential for Covid-19. … The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056].
Categories: Experimental Unapproved Treatments for COVID-19HMR4011
go.drugbank.com/drugs/DB06225ExperimentalIPL 576,092 has previously been investigated as a treatment for asthma.
Lumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnOn August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesInositol 1,4,5-trisphosphate-gated calcium channel ITPR1
go.drugbank.com/bio_entities/BE0004522TargetTransporterHumansInositol 1,4,5-trisphosphate-gated calcium channel that, upon inositol 1,4,5-trisphosphate binding, mediates calcium release from the endoplasmic reticulum (ER) (PubMed:10620513, PubMed:27108797). Undergoes conformational changes upon li...
Synonyms: IP3 receptor isoform 1, Type 1 InsP3 receptorCannabinor
go.drugbank.com/drugs/DB05048ExperimentalCannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
Enoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnEnoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with congestive heart failure. Trials were halted...
Alferminogene tadenovec
go.drugbank.com/drugs/DB05306InvestigationalAlferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease
Lactose
go.drugbank.com/drugs/DB04465ApprovedInvestigationalWithdrawnIt is used in pharmacy for tablets, in medicine as a nutrient, and in industry.